369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers

• Afshin Dowlati,
• Andrea Bullock,
• Susanna Ulahannan,
• Manish Patel,
• Shubham Pant,
• Marsha Crochiere,
• Jian Chen,
• Devalingam Mahalingam,
• Mary Mulcahy,
• Lou Vaickus,
• Suming Wang,
• Melanie Vincent,
• Michael Cieslewicz,
• Jing Watnick,
• Dejan Juric,
• Susanne Fyfe,
• Randolph Watnick

Affiliations

Afshin Dowlati

7Case Western, Cleveland, OH, USA

Andrea Bullock

8Beth Israel Deaconess Hospital, boston, MA, USA

Susanna Ulahannan

4University of Oklahoma Health Sciences C, OKC, OK, USA

Manish Patel

General Medicine, University Hospital Wishaw, Wishaw, UK

Shubham Pant

Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA

Marsha Crochiere

13Vigeo Therapeutics, Cambridge, MA, USA

Jian Chen

Imperial College Healthcare NHS Trust, London, UK

Devalingam Mahalingam

1Northwestern University Medical School, Chicago, IL, USA

Mary Mulcahy

1Northwestern University Medical School, Chicago, IL, USA

Lou Vaickus

12aktaPD/Vigeo Therapeutics, Boston/Cambridge, MA, USA

Suming Wang

13Vigeo Therapeutics, Cambridge, MA, USA

Melanie Vincent

13Vigeo Therapeutics, Cambridge, MA, USA

Michael Cieslewicz

13Vigeo Therapeutics, Cambridge, MA, USA

Jing Watnick

13Vigeo Therapeutics, Cambridge, MA, USA

Dejan Juric

Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Susanne Fyfe

9Vigeo Therapeutics, Cambridge, MA, USA

Randolph Watnick

10Boston Children’s Hospital, Boston, MA, USA